Prognostic and predictive factors in early-stage breast cancer.

By M. Cianfrocca, L. Goldstein. The Oncologist, 2004

671 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. (2006, background): “stage disease [2]; locally advanced breast cancer (LABC), a very rare disease, does not exceed 5% of the total diagnosed breast cancer cases.”
Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients (2007, result): “These findings are in agreement with the known correlation between increased breast cancer mortality risk and increasing tumor stage, size, grade, or regional lymph node metastases [18,19].”
The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. (2012, neutral): “…lower tumour grade (well-differentiated), absence of comorbidities (such as cardiovascular disease, diabetes and other cancers), favourable genetic profile, human epidermal growth factor receptor type 2 (HER2/ neu ) not overexpressed and positive oestrogen/progesterone receptor status [6, 71, 72].”